Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft scoping review: change in lean mass during… — submissions

The 7 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-017/2
Series
Public comment period
Version
1.0
Published
21 Jul 2026
Last reviewed
21 Jul 2026
Next review
21 Jul 2027
Identifier
10.71829/cei.cp.17
Certainty
Not rated
Cycle
2026 Q2
Window
08 May 2026 – 22 Jun 2026
Status
Closed
Submissions
7

§2Submissions and responses

7 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Georgiana Mountstephen, MSc (Epidemiology) Academic clinical pharmacology unit
DRAFT-LEAN-MASS-SC/007 received 17 May 2026

Results at materially different follow-up durations are pooled

Contributing trials report the outcome at durations ranging across more than a year. The draft pools them into a single estimate. The respondent states that a mean at one duration and a mean at another are not estimates of the same quantity when the effect is still changing.

The respondent proposes that estimates be reported by duration band.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted08 Jul 2026

The secretariat accepts this submission. Pooling across durations assumes a plateau the contributing trials do not demonstrate.

Estimates are now reported by duration band, with the number of contributing trials and participants in each band stated, and no estimate is pooled across bands.

Dr Liesbeth Quenneville, MPharm, MRPharmS Academic nephrology unit
DRAFT-LEAN-MASS-SC/003 received 21 May 2026

The review does not say when it will be updated or what would trigger an update

The respondent states that a synthesis in a field where trials report frequently is out of date from the day it is published, and that a reader has no way to know whether the version in front of them is current.

The respondent proposes a stated trigger for an update as well as a scheduled review date.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseAccepted15 Jul 2026

The secretariat accepts this submission. A review date alone tells a reader when the document will be looked at, not whether it should already have been.

Every synthesis now records a scheduled review date and a stated update trigger, being the reporting of a trial that would materially change the contributing evidence, and the registered trials capable of triggering an update are listed by name.

Dr Ottoline Fitzgerald-Nwosu, MD, MRCP Independent analytical consultancy
DRAFT-LEAN-MASS-SC/002 received 24 May 2026

The review protocol is described but its registration record is not linked

The respondent asks for the prospective registration record of the review protocol so that the registered outcomes can be compared with the reported ones.

The respondent states that without it the claim of prospective registration cannot be checked.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseAccepted in part23 Jul 2026

The secretariat accepts this submission in part. The protocol is published in full on the Institute site with its version history, which permits the comparison the respondent asks for. Where an external registration identifier is not held by the Institute, the review says so rather than supplying one.

Each synthesis now links its own protocol with the version in force at screening, and states explicitly where an external registration identifier is not held, so that the absence is a recorded fact.

Dr Dmitri Nordhagen, PhD (Chemistry), MRSC University department of pharmacy practice
DRAFT-LEAN-MASS-SC/004 received 28 May 2026

The same concern is used to downgrade in two domains

The draft downgrades for both indirectness and imprecision citing the same feature of the contributing trials. The respondent states that this double-counts a single concern and produces a rating lower than the framework supports.

The respondent proposes that the rating be raised by one level.

Declared interest. Is a trustee of a patient organisation that has received a restricted educational grant from a manufacturer in the class under assessment.
Secretariat responseAccepted in part01 Jul 2026

The secretariat accepts this submission in part. The double count is real in one of the two outcomes identified and not in the other, where the two domains rest on different features.

The rating for the first outcome has been raised by one level and the domain reasoning restated, and the reasoning for the second has been rewritten to make clear that the two downgrades rest on different features of the evidence.

Dr Zebedee Zaleski-Mbeki, PhD (Pharmaceutics) Endocrine surgery service
DRAFT-LEAN-MASS-SC/001 received 01 Jun 2026

Analytical surveys are treated as evidence about suppliers when they establish only what was in a sample

Several included surveys purchased material anonymously and analysed it. The respondent states that where the chain from a named supplier to the analysed vial cannot be documented, the result describes a sample and not a supplier.

The respondent proposes that provenance be an explicit eligibility dimension, with surveys reported separately according to whether it could be established.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseAccepted15 Jul 2026

The secretariat accepts this submission. Moderate certainty evidence from the included surveys supports statements about material circulating in a market; it does not support statements about any named supplier's output.

Provenance is now assessed for every included survey and reported as a study characteristic, surveys without establishable provenance are reported separately rather than pooled with those that have it, and no supplier-level inference is drawn from a sample-level result.

Dr Ludmila Tollemache, PharmD, PhD University teaching hospital, department of endocrinology
DRAFT-LEAN-MASS-SC/006 received 13 Jun 2026

Absence of evidence is presented in a form a reader will take as negative evidence

Where the Institute has identified no study, the draft states that no evidence was found. In several places that sentence sits immediately after a paragraph describing an adverse outcome, and the juxtaposition invites the reading that the compound was studied and found wanting.

The respondent proposes a standing formulation, used identically wherever the situation arises, distinguishing an outcome that was studied and not demonstrated from an outcome that has not been studied at all.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted15 Jul 2026

The secretariat accepts this submission. The two states are different, they support different decisions, and the draft rendered them in language a reader could not reliably separate.

A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at a glance.

Dr Jolyon Grünbaum-Sowande, MD, FRCP Independent evidence-synthesis consultancy
DRAFT-LEAN-MASS-SC/005 received 17 Jun 2026

Baseline imbalance in a small contributing trial is not remarked on

The respondent identifies a small contributing trial with a baseline difference in the outcome variable, and states that the difference is large enough to account for a share of the reported effect.

The respondent asks that the trial be excluded or that the imbalance be addressed.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseNoted, no amendment14 Jul 2026

The secretariat notes this submission. The imbalance is recorded in the risk-of-bias assessment for that trial, in the domain concerning the randomisation process, where the respondent may not have looked.

No amendment arises. The judgement and the supporting figures are already reported at domain level for that study, and a sensitivity analysis omitting it is reported in the results, which does not change the direction of the estimate.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.